Mañana nueva sesión de nuestro ciclo formativo #latido 2.0.

🗓️ Jueves 18 abril 08:15 h

🔈”Ultrafiltracion periférica en pacientes con insuficiencia cardiaca” por Víctor Donoso Trenado de Insuficiencia Cardiaca y Trasplante

Toda la info, acceso y acreditación desde svcardio.org/latido-2-0 y Organon España

Lipoproteina (a) y eventos CV en diferentes subgrupos de pacientes JACC Journals

🧷 Se asocia con un riesgo ⤴️ de eventos CV independientemente del sexo, etnia, riesgo CV o valores de c-LDL

🧷 Mayor impacto en pacientes con DM2 (P interacción=0,0056)

jacc.org/doi/10.1016/j.…

Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography. Review in European Society of Cardiology Journals

academic.oup.com/eurheartj/adva…

Menos de dos semanas para iniciar nuestra gran reunión del año!

🗓️ 24 y 26 de abril en #Valencia 🏨

🔈XLI Congreso de las Enfermedades Cardiovasculares de SVCardio

🔈 Programa e info en svcardio.org/congresocardio…

No te lo pierdas, os esperamos en Valencia❗️

Impressive results for TAVI vs SAVR in patients with severe aortic stenosis at low or intermediate risk #ACC24 NEJM

DEDICATE-DZHK6 randomized trial in 🇩🇪 including 1414 👥

TAVI was non-inferior to SAVR. At 1 year TAVI was associated with a ⤵️ risk of:

-💀(2.6% vs 6.2%,…

Do we need beta-blockers 💊 in patients with myocardial infarction & preserved LVEF? REDUCE-AMI trial #ACC24 NEJM

🔊 Long-term beta-blocker treatment did not lead to a ⤵️ risk of the composite primary end point of death or new myocardial infarction than no beta-blocker use…

Good results for olezarsen, an antisense oligonucleotide targeting APO-C3 in patients with moderate hypertriglyceridemia and ⤴️ CV risk or severe HTG #ACC24 NEJM

phase 2b RCT Bridge–TIMI 73a

➖Consistent ⤵️ of TG levels by 50%

➖ 18-25% ⤵️ in Apo B or non-HDL cholesterol…

STEP-HFpEF DM #ACC24 NEJM

Among patients with obesity, HFpEF and type 2 diabetes, semaglutide led to significant differences vs placebo in:

- HF symptoms: 7 points-KCCQ improvement
- Body weight ⤵️ 6%
- Win Ratio 1.58
- ⤵️ CRP levels

nejm.org/doi/full/10.10…

RELIEVE-HF trial #ACC24 Interatrial shunt device in patients with #heartfailure across the full range of LVEF

➖ Neutral trial, no benefit on CV events, safe procedure

➖LVEF analysis suggests 🟢 benefit in patients with HFrEF and🔴 harm in patients with LVEF>40%

High Lipoprotein(a): Actionable Strategies for Risk Assessment and Mitigation Soc Esp Cardiología SVCardio Cardiología Preventiva

sciencedirect.com/science/articl…

Beneficio de empagliflozina en pacientes con IC aguda independientemente de la FEVI. Análisis de #empulse European Society of Cardiology

onlinelibrary.wiley.com/doi/full/10.10… Soc Esp Cardiología SVCardio #CardioTwitter

La FDA aprueba el dispositivo TriClip para el tratamiento percutáneo de la IT grave

abbott.mediaroom.com/2024-04-02-Abb…

Metaanálisis CTT. Riesgo de DM2 de nueva aparición con estatinas? The Lancet Diabetes & Endocrinology

Riesgo dosis-depediente
Moderada intensidad —> ⤴️ 10%
Alta intensidad —> ⤴️ 36%

Mayor riesgo en 👥 con prediabetes

Leve aumento HbA1c (0·06%-0·08%)

thelancet.com/journals/landi…

Noncardiovascular morbidity and mortality across left ventricular ejection fraction categories following hospitalization for heart failure #REC Enrique Santas Pau Llàcer Patrícia Palau Rafael de la Espriella Gema Miñana Miguel Lorenzo Hernández Juan Sanchis Julio

Functional mitral regurgitation and #HFpEF : clinical implications and management.

Very interesting review in Journal of Cardiac Failure

☑️ Open access

📎 onlinejcf.com/article/S1071-…

Soc Esp Cardiología SVCardio #CardioTwitter